Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global Preimplantation Genetic Testing Kits (PGT Kits) market was valued at more than USD 500 Million in 2024. The market is projected to grow from USD 580 Million in 2025 to approximately USD 1.1 Billion by 2032, exhibiting a CAGR of around 9.5% during the forecast period.
Preimplantation Genetic Testing (PGT) kits are specialized diagnostic tools used during In Vitro Fertilization (IVF) to analyze embryos for genetic abnormalities before implantation. These kits enable the detection of chromosomal aneuploidies (PGT-A), monogenic/single gene disorders (PGT-M), and structural rearrangements (PGT-SR), thereby increasing the chances of a successful pregnancy and the birth of a healthy child. The technology primarily relies on advanced genomic analysis techniques such as Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR).
The market growth is largely driven by the increasing prevalence of genetic disorders, rising maternal age leading to higher risks of aneuploidy, and growing global acceptance and accessibility of Assisted Reproductive Technology (ART) services. Furthermore, significant technological advancements leading to higher accuracy, faster turnaround times, and reduced costs are key factors. Major market players are actively engaged in strategic initiatives; for instance, in 2023, Illumina launched the VeriSeq PGS kit v2, a CE-IVD marked solution for comprehensive chromosome screening. Thermo Fisher Scientific, PerkinElmer, and Illumina are recognized as the dominant players, collectively holding a significant market share.
Rising Prevalence of Genetic Disorders and Chromosomal Abnormalities
The growing incidence of genetic disorders and aneuploidies in embryos is a primary factor propelling the PGT kits market. A significant percentage of pregnancies in women of advanced maternal age are affected by chromosomal abnormalities, driving the demand for pre-screening. Furthermore, increasing awareness and diagnosis of single-gene disorders like cystic fibrosis and Huntington's disease create a need for PGT-M (monogenic/single gene disorder) testing kits.
Technological Advancements in Genetic Analysis
Continuous innovation in molecular diagnostics, particularly the shift from older FISH-based methods to advanced techniques like Next-Generation Sequencing (NGS) and Array-CGH, is a major market driver. These technologies offer higher accuracy, comprehensive screening capabilities, and faster turnaround times. The development of comprehensive chromosome screening (CCS) kits that can analyze all 24 chromosomes reliably has significantly improved IVF success rates.
The global trend of delayed parenthood is a powerful catalyst. With the average maternal age at first birth increasing in many developed nations, the associated rise in age-related aneuploidy risk directly fuels the adoption of PGT-A (aneuploidy screening).
Supportive regulatory frameworks and government initiatives in some regions that recognize the benefits of PGT for reducing hereditary diseases and improving public health outcomes also contribute to market growth.
MARKET CHALLENGES
High Costs and Reimbursement Limitations
The substantial cost of in vitro fertilization (IVF) cycles combined with the additional expense of PGT presents a significant barrier to widespread adoption. PGT procedures can add thousands of dollars to the total cost of an IVF cycle. In many healthcare systems, insurance coverage for PGT is limited or non-existent, placing the financial burden entirely on patients and limiting access, particularly in price-sensitive markets.
Other Challenges
Ethical and Regulatory Hurdles
The use of PGT, particularly for non-medical reasons like sex selection (PGT for social sexing), raises complex ethical questions and is heavily regulated or banned in many countries. Navigating the diverse and often restrictive legal landscapes across different regions poses a significant challenge for manufacturers and clinics.
Technical Complexities and Expertise Requirements
PGT requires highly specialized laboratory infrastructure and trained personnel, including skilled embryologists and geneticists. The biopsy procedure itself is delicate and carries a small inherent risk to the embryo. Ensuring consistent accuracy and minimizing the risk of misdiagnosis remains a critical operational challenge.
Ethical Concerns and Public Perception
Persisting ethical debates surrounding embryo selection and the potential for "designer babies" act as a significant restraint on market expansion. Public skepticism and cultural or religious objections in certain populations can limit the acceptance and utilization of PGT technologies, affecting market growth in those regions.
Risk of Diagnostic Errors and Mosaicism
While testing accuracy is high, the possibility of a false positive or false negative result remains a concern. A particular challenge is embryonic mosaicism, where a biopsy from one cell may not represent the genetic makeup of the entire embryo. This can lead to the discarding of potentially viable embryos or the transfer of those with abnormalities, creating medical and legal risks that restrain market confidence.
Expansion into Emerging Economies
There is substantial untapped potential in emerging economies across Asia-Pacific, Latin America, and the Middle East. Improving healthcare infrastructure, rising disposable incomes, and growing medical tourism for fertility treatments present significant growth opportunities for PGT kit manufacturers to expand their geographic footprint.
Development of Non-Invasive PGT (niPGT)
The emergence of non-invasive PGT techniques, which analyze cell-free DNA from the blastocyst culture medium instead of performing a trophectoderm biopsy, represents a major opportunity. This approach could reduce costs, simplify the procedure, eliminate risks associated with embryo biopsy, and potentially increase patient acceptance, opening up new market segments.
Integration with Expanded Carrier Screening
Integrating PGT with comprehensive expanded carrier screening (ECS) for prospective parents creates a powerful bundled offering for fertility clinics. This allows for a more complete pre-conception and pre-implantation genetic assessment, providing a significant value proposition and an opportunity for market differentiation and growth.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
PGT-A (Preimplantation Genetic Testing for Aneuploidy) is the dominant and most widely adopted segment due to its critical role in increasing the success rates of in-vitro fertilization procedures. This testing is considered a standard practice in many fertility clinics for embryo selection, as it screens for chromosomal abnormalities that are a leading cause of miscarriage and implantation failure in couples undergoing assisted reproductive technology. Its widespread adoption is driven by the growing preference for single embryo transfer to avoid multiple pregnancies, coupled with the rising maternal age globally, which is directly correlated with an increased incidence of embryonic aneuploidy. |
| By Application |
|
Fertility Clinics constitute the leading application segment for PGT kits, as they are the primary point-of-care for patients seeking assisted reproductive services. These clinics integrate PGT as a core component of their treatment protocols to enhance clinical outcomes, which is a major factor in patient choice and clinic reputation. The growth in this segment is fueled by the increasing global prevalence of infertility and the growing societal acceptance and utilization of IVF treatments. Furthermore, these clinics are often at the forefront of adopting new technological advancements in genetic screening to offer state-of-the-art services. |
| By End User |
|
Clinical Diagnostic Centers lead the end-user segment, as they are the main facilities processing and interpreting PGT analyses for patient care. These centers are heavily invested in high-throughput, accurate genetic analysis platforms and have established workflows for handling embryo biopsies. Their dominance is reinforced by the need for certified laboratories with stringent quality control measures to ensure reliable results that directly influence critical patient decisions. The trend towards consolidation and the formation of large, specialized diagnostic service providers further strengthens the position of this segment. |
| By Technology |
|
Next-Generation Sequencing (NGS) has emerged as the leading technology segment, revolutionizing PGT by enabling comprehensive chromosome screening with high resolution and accuracy. The superiority of NGS lies in its ability to detect a wide range of chromosomal abnormalities from a single biopsy sample, including aneuploidies, segmental imbalances, and mosaicism, providing a more complete genetic profile of the embryo. Its increasing affordability, automation capabilities, and widespread adoption by major kit manufacturers solidify its dominance, making it the gold standard for comprehensive preimplantation genetic testing. |
| By Test Purpose |
|
Chromosomal Abnormalities Screening is the foremost segment by test purpose, primarily driven by the high volume of PGT-A tests performed to improve IVF success rates. This purpose addresses the most common genetic issue in embryos, particularly for women of advanced maternal age or those with a history of recurrent pregnancy loss. The clinical utility of identifying euploid embryos for transfer is well-established and represents the largest application of PGT globally. This segment's growth is further propelled by ongoing technological improvements that make comprehensive screening more accessible and reliable for a broader patient population. |
A Consolidated Market Led by Established Genomics Giants
The global Preimplantation Genetic Testing Kits market is characterized by a high degree of consolidation, with the top five players accounting for a significant majority of the revenue share as of 2024. Thermo Fisher Scientific, Illumina, and PerkinElmer are the dominant forces, leveraging their extensive portfolios of genetic analysis instruments, reagents, and consumables. These companies benefit from established global distribution networks, strong brand recognition, and substantial research and development capabilities, which are critical for innovating in the technically demanding PGT space. Their products are widely adopted in hospitals and testing laboratories worldwide, forming the backbone of many IVF clinic workflows. The market structure is further reinforced by strategic acquisitions and partnerships aimed at expanding technological capabilities and geographic reach.
Beyond the market leaders, a number of specialized and regional players hold significant positions by focusing on niche technologies or specific geographic markets. Companies like Takara Bio bring expertise in specific amplification and detection chemistries, while others such as BASECARE and Jabrehoo have carved out roles, particularly within the Asia-Pacific region. These companies often compete on factors such as cost-effectiveness, customization, and superior customer support for specific PGT applications like PGT-M (monogenic disorders) or PGT-SR (structural rearrangements). The competitive dynamics are further influenced by the continuous evolution of testing technologies, including the shift towards comprehensive chromosome screening and next-generation sequencing, which presents opportunities for agile innovators.
List of Key Preimplantation Genetic Testing Kits Companies ProfiledThermo Fisher Scientific
PerkinElmer, Inc.
BASECARE
Jabrehoo Med Tech
Agilent Technologies
CooperSurgical, Inc.
Genea Limited
IVFtech A/S
Vitrolife AB
Natera, Inc.
Good Start Genetics
Global market analysis for Preimplantation Genetic Testing Kits (PGT Kits) reveals a trajectory of significant growth from its 2024 valuation, projected to reach a multimillion-dollar figure by 2032. This expansion is underpinned by a steady Compound Annual Growth Rate (CAGR) during the forecast period. The market dynamics are largely driven by increasing demand from the in-vitro fertilization (IVF) sector and growing awareness of genetic screening. The United States represents a major market, while China is emerging as a key contributor to future growth, expected to achieve a substantial market size by the end of the forecast period.
Other TrendsPGT-A Segment Dominance and Technological Advancements
The Preimplantation Genetic Testing for Aneuploidy (PGT-A) segment is a primary driver within the market, poised to reach a significant valuation by 2032 with a robust CAGR over the next several years. This dominance is linked to its critical role in improving the success rates of IVF procedures by screening embryos for chromosomal abnormalities. Concurrently, technological advancements in next-generation sequencing (NGS) are enhancing the accuracy, efficiency, and affordability of PGT kits. Leading manufacturers are continuously investing in R&D to introduce more advanced and automated testing solutions.
Consolidated Competitive Landscape and Regional DynamicsThe competitive environment is characterized by the presence of established global players, with the top five companies accounting for a significant share of the total market revenue in 2024. Key manufacturers such as Thermo Fisher, PerkinElmer, and Illumina lead the market through extensive product portfolios and strong distribution networks. Geographically, the market is segmented across North America, Europe, Asia, South America, and the Middle East & Africa. North America, particularly the U.S., holds a leading position, while the Asia-Pacific region, led by China and Japan, is anticipated to exhibit the highest growth potential due to improving healthcare infrastructure and rising disposable incomes.
Regional Analysis: Preimplantation Genetic Testing Kits (PGT Kits) MarketEurope
Europe represents a mature and significant market for PGT kits, characterized by a diverse regulatory landscape across its member states. Countries like the United Kingdom, Spain, and Germany are at the forefront, with well-established ART sectors and supportive regulatory frameworks for genetic testing. The region shows a strong emphasis on ethical guidelines, which shape the application of PGT, particularly regarding PGT for monogenic disorders (PGT-M) and HLA matching. Public funding and reimbursement for IVF cycles, including PGT in some countries, play a crucial role in market accessibility. There is a growing trend towards the standardization of PGT protocols across laboratories to ensure quality and reliability. However, variations in national laws concerning embryo research and testing create a patchwork of opportunities and challenges for kit manufacturers operating across the continent.
Asia-Pacific
The Asia-Pacific region is identified as the fastest-growing market for PGT kits, fueled by improving healthcare infrastructure, rising disposable incomes, and growing medical tourism, especially in countries like China, India, and Japan. Increasing awareness about genetic disorders and the benefits of family planning is driving adoption. China, in particular, is experiencing rapid market expansion due to government initiatives and a large patient base. Japan's market is influenced by its advanced technological base and an aging population seeking assisted reproduction. However, the market growth is uneven, with affordability and varying levels of regulatory oversight posing challenges in some developing economies. Cultural factors and ethical considerations also influence the acceptance and application of PGT technologies across different countries within the region.
South America
The South American market for PGT kits is emerging, with Brazil and Argentina serving as the primary growth engines. The market is driven by an increasing number of fertility clinics and a gradual rise in awareness about advanced reproductive technologies. Economic fluctuations and disparities in healthcare access can limit uniform growth across the continent. Regulatory frameworks are still evolving, which can sometimes slow down the introduction of new testing kits. Nevertheless, there is a growing patient demand for higher success rates in IVF procedures, which is encouraging clinics to adopt PGT. Medical tourism also contributes to market dynamics, with patients traveling to more established centers within the region.
Middle East & Africa
The Middle East and Africa region presents a market with high growth potential but is currently characterized by limited penetration of PGT kits. The Gulf Cooperation Council (GCC) countries, such as the UAE and Saudi Arabia, are the most active markets, driven by high disposable incomes, government healthcare investments, and a growing focus on women's health. A significant cultural and religious emphasis on family planning supports the adoption of ART. In contrast, many parts of Africa face challenges related to infrastructure, affordability, and access to specialized care, which restrict market growth. The region also sees a notable prevalence of certain genetic disorders, which could drive future demand for PGT-M kits as awareness and healthcare systems improve.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Preimplantation Genetic Testing Kits market was valued at USD 500 million in 2024 and is projected to reach USD 1.1 billion by 2032, growing at a CAGR of 9.5% during the forecast period.
-> Key players include Thermo Fisher, PerkinElmer, Illumina, Takara Bio, BASECARE, and Jabrehoo, with the top five players holding a significant market share in 2024.
-> Key growth drivers include increasing prevalence of genetic disorders, rising maternal age, and growing adoption of Assisted Reproductive Technology (ART) services.
-> North America currently leads the market, while Asia-Pacific is expected to show significant growth potential.
-> Emerging trends include advancements in Next-Generation Sequencing (NGS) technologies, development of more accurate PCR-based tests, and expansion of PGT applications beyond traditional IVF.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates